SCHEMBL3280962

SCHEMBL3280962

COc1ccc(-c2cc3nc(Cl)ccc3c(Cl)n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.48
AURKB Q96GD4 1/20 0.48
KDM4E B2RXH2 5/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPT P10636 2/20 0.47
ACACA Q13085 1/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
SYK P43405 4/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PLA2G2A P14555 2/20 0.44
DYRK1A Q13627 1/20 0.44
DHODH Q02127 1/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ACP1 P24666 2/20 0.43
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3280710 0.86 KDM4E (0.47) AURKAAURKBKDM4EALDH1A1MAPT
SCHEMBL3280742 0.82 KDM4E (0.53) AURKAAURKBKDM4EALDH1A1MAPT
SCHEMBL4763766 0.80 NPC1 (0.55) AURKAAURKBKDM4EALDH1A1MAPT
SCHEMBL3280663 0.80 SYK (0.71) AURKAAURKBKDM4EALDH1A1MAPT
SCHEMBL3280565 0.77 DHODH (0.55) AURKAAURKBKDM4EALDH1A1MAPT
SCHEMBL3284948 0.76 ACP1 (0.59) KDM4EALDH1A1MAPTHTTSYK
SCHEMBL4763954 0.76 NPC1 (0.58) AURKAAURKBKDM4EALDH1A1MAPT
SCHEMBL6534170 0.76 KDM4E (0.58) AURKAAURKBKDM4EALDH1A1MAPT
SCHEMBL3284979 0.75 SYK (0.59) AURKAAURKBKDM4EALDH1A1MAPT
SCHEMBL4772556 0.73 NPC1 (0.47) AURKAAURKBKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705151-B2 1,6 Naphthridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2010-04-27 US disclosed
US-7705151-B2 1,6 Naphthridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2010-04-27 US disclosed
US-7705151-B2 1,6 Naphthridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2010-04-27 US disclosed
US-7678911-B2 1,6 naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-7678911-B2 1,6 naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-7678911-B2 1,6 naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20090171089-A1 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-07-02 US disclosed
US-20090171089-A1 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-07-02 US disclosed
US-20090171089-A1 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-07-02 US disclosed
US-20080114024-A1 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE CYWIN CHARLES L 2008-05-15 US disclosed
US-20080114024-A1 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE CYWIN CHARLES L 2008-05-15 US disclosed
US-20080114024-A1 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE CYWIN CHARLES L 2008-05-15 US disclosed
US-7321041-B2 1,6 Naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2008-01-22 US disclosed
US-7321041-B2 1,6 Naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2008-01-22 US disclosed
US-20030229090-A1 1,6 Naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-12-11 US disclosed
US-20030158195-A1 1,6 naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-08-21 US disclosed
WO-2003057695-A1 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2003-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229090-A1 1,6 Naphthyridines useful as inhibitors of SYK kinase SYK, IRAK1, BTK AURKA 1048/4885AURKB 1095/4885KDM4E 1930/4885
US-20080114024-A1 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE SYK, IRAK1, IRAK3 AURKA 1473/4885AURKB 1280/4885KDM4E 1585/4885
US-20090171089-A1 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE SYK, IRAK1, IRAK3 AURKA 1493/4885AURKB 1370/4885KDM4E 1799/4885
US-20030158195-A1 1,6 naphthyridines useful as inhibitors of SYK kinase SYK, IRAK1, BTK AURKA 1048/4885AURKB 1095/4885KDM4E 1930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.